Cns Pharmaceuticals Inc Stock

$0.88

5.02% yesterday

Nasdaq, Jun 27, 10:08 pm CET

ISIN

US18978H1023

Symbol

CNSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Cns Pharmaceuticals Inc Stock price

$0.88

-155,249.12 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.04 5.02%

ISIN

US18978H1023

Symbol

CNSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$4.8m

Enterprise Value

$-8.0m

Net debt

$-12.8m

Cash

$13.1m

Shares outstanding

2.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

0.47

P/B

0.24

Financial Health

Equity Ratio

70.99%

Return on Equity

-240.55%

ROCE

-143.09%

ROIC

Debt/Equity

0.02

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-15.7m | -

EBIT

$-15.7m

Net Income

$-15.6m | $-67.7m

Free Cash Flow

$-17.2m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

10.24% | -

EBIT

10.22%

Net Income

10.60% | -355.38%

Free Cash Flow

-37.25%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-5.72

FCF per Share

$-5.84

Short interest

8.44%

Employees

5.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Cns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Cns Pharmaceuticals Inc forecast:

6x Buy

75%

2x Hold

25%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Cns Pharmaceuticals Inc forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Cns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.59 5.59	24% 24% -
- Research and Development Expense	10 10	22% 22% -
EBITDA	-16 -16	10% 10% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-16 -16	10% 10% -
Net Profit	-16 -16	11% 11% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cns Pharmaceuticals Inc Stock News

Neutral

Accesswire

●

4 days ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and cen...

Neutral

Accesswire

●

23 days ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers ...

Neutral

Accesswire

●

about one month ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel tre...

More Cns Pharmaceuticals Inc News

Company Profile

CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.

Head office	United States
CEO	John Climaco
Employees	5
Founded	2017
Website	cnspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now